Texans Receiver Diagnosed with Leukemia


HOUSTON- A Houston Texans rookie receiver has been diagnosed with leukemia.

John Metchie III, a rookie 2nd round pick for the Houston Texans, has posted his positive diagnoses for APL, or acute promyelocytic leukemia.

According to the rarediseases.org, APL is a blood cancer characterized by a marked increase in the white blood cells called promyelocytic. They are a kind of immature white blood cell.

It is a very rare disease as it only develops in about 700 people a year. Even though it’s rare, it is considered one of the more curable types of cancer.

Metchie, 22, was a standout receiver at Alabama and even though he was injured, the Texans still took him at 44 in the 2022 NFL Draft. In two years as a starter at Bama, Metchie had 151 catches, 2,058 yards, and 14 touchdowns. He did tear his ACL in the SEC Championship game.

Due to the injury, Metchie was not able to participate in the NFL Combine earlier this year. Throughout the pre-draft process, APL was not discovered.

In a social media post, Metchie said that this will likely keep him from playing this season.

Many players have been diagnosed with different types of cancer. Current Arizona running back James Conner and former NFL safety Eric Berry were both diagnosed with Hodgkin's Lymphoma, linebacker Mark Herzlich with Ewing’s Sarcoma, and Trent Williams, one of the leagues top offensive tackles, was diagnosed with dermatofibrosarcoma protuberans, a skin cancer.

Subscribe to the LIVE! Daily

The LIVE! Daily is the "newspaper to your email" for San Angelo. Each content-packed edition has weather, the popular Top of the Email opinion and rumor mill column, news around the state of Texas, news around west Texas, the latest news stories from San Angelo LIVE!, events, and the most recent obituaries. The bottom of the email contains the most recent rants and comments. The LIVE! daily is emailed 5 days per week. On Sundays, subscribers receive the West Texas Real Estate LIVE! email.


Most Recent Videos

Post a comment to this article here:

X Close